Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810095 | 0.88 | KDM4E (0.45) | LOXL2TLR7MAOAMAOBKDM4E | |
| SCHEMBL3265308 | 0.83 | LOXL2 (0.49) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23229998 | 0.83 | LOXL2 (0.51) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6155906 | 0.82 | LOXL2 (0.55) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1253989 | 0.81 | LOXL2 (0.58) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL24197399 | 0.81 | LOXL2 (0.50) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL15826444 | 0.81 | S1PR2 (0.52) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL28252734 | 0.81 | CYP1A2 (0.56) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL12608425 | 0.80 | LOXL2 (0.49) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL17260150 | 0.80 | SLC2A1 (0.52) | LOXL2HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| EP-1934238-B1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-19 | — | — | US | disclosed |
| EP-1554239-A2 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | HCRTR2, HCRTR1, GIPR | LOXL2 4004/4885HTR1A 104/4885ADRA1D 91/4885 |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | LOXL2 3908/4885HTR1A 1982/4885ADRA1D 3322/4885 |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | LOXL2 3908/4885HTR1A 1982/4885ADRA1D 3322/4885 |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | LOXL2 3908/4885HTR1A 1982/4885ADRA1D 3322/4885 |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | LOXL2 3908/4885HTR1A 1982/4885ADRA1D 3322/4885 |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | LOXL2 4004/4885HTR1A 104/4885ADRA1D 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.